Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections

The management of SARS-CoV-2 has not yet been clearly determined and is based on potential therapies evaluated during the SARS-CoV and MERS-CoV outbreaks. An emerging potential therapeutic approach currently being evaluated in numerous clinical trials is the remdesivir agent, which acts on COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Saqrane, S., El Mhammedi, M.A., Lahrich, S., Laghrib, F., El Bouabi, Y., Farahi, A., Bakasse, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039503/
https://www.ncbi.nlm.nih.gov/pubmed/33857725
http://dx.doi.org/10.1016/j.jiph.2021.02.006
Descripción
Sumario:The management of SARS-CoV-2 has not yet been clearly determined and is based on potential therapies evaluated during the SARS-CoV and MERS-CoV outbreaks. An emerging potential therapeutic approach currently being evaluated in numerous clinical trials is the remdesivir agent, which acts on COVID-19 by interfering with key steps in the virus replication cycle. It is considered a therapeutic option to be evaluated against COVID-19, based on data on its in vitro and in vivo activity against MERS-CoV and SARS-CoV coronaviruses. In this work, we provide an overview of remdesivir’s discovery, mechanism of action, and the current studies exploring its clinical effectiveness. Recommendations for its use against COVID-19 infection are also summarized.

Ejemplares similares